Fig. 3.

Antifibrinolytic therapy did not significantly improve the bleeding phenotype or the response to recombinant activated factor VII (rFVIIa) or recombinant factor VIII (rFVIII) in mice with congenital hemophilia A. (A, E) Individual bleeding profiles of treated mice: graphical representation of bleeding profiles, in which horizontal lines represent the entire bleeding profile of a single mouse, and each bar in a line represents a single bleeding episode for that mouse. (B–D, F–H) Total blood loss (B, F), bleeding time (C, G) and spontaneous bleeds (D, H) of FVIII^−/− mice are shown as individual observations, with horizontal and error bars representing mean ± standard error of the mean. No significant differences for tranexamic acid (TXA) alone versus vehicle or for factor treatment alone versus factor treatment + TXA were detected for blood loss, bleeding time, or the number of spontaneous bleeds. Data were analyzed with the Kruskal–Wallis test, with Dunn’s test to adjust for multiple comparisons between all groups, except for wild-type (WT) mice. *P < 0.05, **P < 0.01, and ***P < 0.001. FVIII^−/− mice were used, unless noted otherwise. Hgb, hemoglobin.